Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children.
作者信息
Li Xiaohe, Wu Liwen, Qu Youzhi, Cao Mengli, Feng Jiaqi, Huang Hua, Liu Yi, Lu Hongzhou, Liu Quanying, Liu Yingxia
机构信息
Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen, 518112, P. R. China.
School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, P. R. China.
出版信息
Signal Transduct Target Ther. 2022 Jun 28;7(1):203. doi: 10.1038/s41392-022-01023-w.
Abstract
摘要
相似文献
1
Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children.
Signal Transduct Target Ther. 2022 Jun 28;7(1):203. doi: 10.1038/s41392-022-01023-w.
2
SARS-CoV-2 Omicron subvariant spike N405 unlikely to rapidly deamidate.
Biochem Biophys Res Commun. 2023 Jul 23;666:61-67. doi: 10.1016/j.bbrc.2023.04.088. Epub 2023 May 2.
3
Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.
N Engl J Med. 2022 Oct 27;387(17):1620-1622. doi: 10.1056/NEJMc2209306. Epub 2022 Oct 5.
4
Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
Viruses. 2022 Jun 18;14(6):1334. doi: 10.3390/v14061334.
5
Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
Emerg Infect Dis. 2022 Jun;28(6):1274-1275. doi: 10.3201/eid2806.220503. Epub 2022 Mar 31.
6
Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
Front Immunol. 2022 Jun 30;13:908478. doi: 10.3389/fimmu.2022.908478. eCollection 2022.
7
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
Nat Commun. 2022 May 26;13(1):2956. doi: 10.1038/s41467-022-30580-5.
8
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
9
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428. doi: 10.15585/mmwr.mm7111e1.
10
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
引用本文的文献
1
Impact of Vaccination and Public Health Measures on the Severity of SARS-CoV-2 Omicron Infections in China: A Systematic Review and Meta-Regression Analysis.
Vaccines (Basel). 2025 Jul 12;13(7):747. doi: 10.3390/vaccines13070747.
2
Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China.
Front Med (Lausanne). 2023 Aug 29;10:1240340. doi: 10.3389/fmed.2023.1240340. eCollection 2023.
3
Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients.
Heliyon. 2023 Jul 11;9(7):e18093. doi: 10.1016/j.heliyon.2023.e18093. eCollection 2023 Jul.
4
Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.
Nat Commun. 2023 Mar 23;14(1):1620. doi: 10.1038/s41467-023-37059-x.
5
Cold chain-affiliated associated SARS-CoV-2 omicron BA.2 infections, Qingdao, Shandong, China, 2022.
Arch Med Sci. 2023 Jan 13;19(1):288-291. doi: 10.5114/aoms/155882. eCollection 2023.
6
Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study.
Phytomedicine. 2023 Mar;111:154665. doi: 10.1016/j.phymed.2023.154665. Epub 2023 Jan 11.
7
Clinical characteristics of children with omicron SARS-CoV-2 infection in Changchun, China from march to april 2022: A retrospective study.
Front Pediatr. 2022 Nov 15;10:990944. doi: 10.3389/fped.2022.990944. eCollection 2022.
8
Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings.
Front Immunol. 2022 Oct 25;13:947602. doi: 10.3389/fimmu.2022.947602. eCollection 2022.
本文引用的文献
1
Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak.
Clin Infect Dis. 2022 Aug 24;75(1):e44-e49. doi: 10.1093/cid/ciac203.
2
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
3
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas.
Am J Pathol. 2022 Apr;192(4):642-652. doi: 10.1016/j.ajpath.2022.01.007. Epub 2022 Feb 3.
4
Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees.
J Infect. 2022 Apr;84(4):579-613. doi: 10.1016/j.jinf.2022.01.004. Epub 2022 Jan 10.
5
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.
J Chem Inf Model. 2022 Jan 24;62(2):412-422. doi: 10.1021/acs.jcim.1c01451. Epub 2022 Jan 6.
Zotero 插件